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Abstract
Efforts at preventing pneumococcal disease are a national health priority, particularly in older 
adults and especially in post-acute and long-term care settings (PA/LTC). The Advisory 
Committee on Immunization Practices (ACIP) recommends that all adults ≥ 65, as well as adults 
aged 18–64 with specific risk factors, receive both the recently introduced polysaccharide-protein 
conjugate vaccine against 13 pneumococcal serotypes (PCV13) as well as the polysaccharide 
vaccine against 23 pneumococcal serotypes (PPSV23). Nursing facility licensure regulations 
require facilities to assess the pneumococcal vaccination status of each resident, provide education 
regarding pneumococcal vaccination, and administer the appropriate pneumococcal vaccine when 
indicated. Sorting out the indications and timing for PCV13 and PPSV23 administration is 
complex, and presents a significant challenge to healthcare providers. Here, we discuss the 
importance of pneumococcal vaccination for older adults, detail AMDA – The Society for Post-
Acute and Long-Term Care Medicine (The Society)’s recommendations for pneumococcal 
vaccination practice and procedures, and offer guidance to PA/LTC providers supporting the 
development and effective implementation of pneumococcal vaccine policies.
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BACKGROUND
The Advisory Committee on Immunization Practices (ACIP) has long recommended 
pneumococcal vaccination for older adults and those with certain chronic health conditions 
[1]. In 2014, ACIP released updated recommendations that call for the combined use of two 
separate pneumococcal vaccines [2]. Since their release, AMDA - The Society for Post-
Acute and Long-Term Care Medicine (The Society) has fielded a number of inquiries from 
providers, facilities and surveyors regarding application of the ACIP recommendations to 
post-acute and long-term care (PA/LTC) settings. Questions received have focused on the 
impact of pneumococcal disease and pneumococcal vaccination in PA/LTC populations; 
financial coverage of the vaccine; and operational issues. Operational queries have included 
questions surrounding appropriate intervals for vaccination, whether nursing homes were 
required to offer either and/ or both vaccines, whether standing orders are allowed, and how 
to address lack of access to past vaccination history.
The Society strongly supports pneumococcal vaccination consistent with ACIP and Centers 
for Disease Control and Prevention (CDC) recommendations. The Society also understands 
the need to respond to the various questions raised about pneumococcal vaccination in 
PA/LTC settings. To that end, The Society’s Infection Advisory Committee (IAC) conducted 
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an environmental scan. This included assembling and thematically grouping questions 
received from September 2014 through May 2016. In addition, the IAC conducted a limited 
number of detailed interviews with select stakeholders, including state survey agency 
representatives, PA/LTC practitioners, and members of other professional societies. General 
information from survey citations was reviewed and pertinent literature and website reviews 
were conducted.
Based on this work, the IAC developed a series of educational and implementation tools to 
assist PA/LTC providers when assessing residents for pneumococcal vaccination needs. To 
further assist with guideline compliance, the materials present multiple clinical vignettes for 
practitioners [3]. Here, we present the results of these efforts, The Society’s policy 
statement, and introduce the tools developed.
PNEUMOCOCCAL DISEASE SERIOUSLY IMPACTS THE HEALTH OF OLDER 
ADULTS
Streptococcus pneumoniae (pneumococcus) remains a serious health threat in the United 
States, and one that is potentially preventable [2]. The leading bacterial cause of community 
acquired pneumonia (CAP), Streptococcus pneumoniae accounts for 20 to 60% of cases [4]. 
However, Streptococcus pneumoniae causes a variety of other infections as well, such as 
bacterial otitis media typically seen in children and invasive pneumococcal disease. The term 
invasive pneumococcal disease (IPD) refers to any infection of a normally sterile site by 
Streptococcus pneumoniae. Examples of IPD include bacteremia, meningitis, arthritis, and 
endocarditis. IPD represents roughly one quarter of all pneumococcal infections and the 
incidence of IPD increases with age [5].
Before the advent of antibiotics in the early 1900’s, IPD was nearly always fatal [6]. The 
development of sulfa drugs, penicillin and subsequent antibiotics occasioned a significant 
reduction in pneumococcal-related morbidity and mortality [7]. Antibiotics became the 
mainstay of treatment for pneumococcal disease. Despite the overall reduction in mortality 
from pneumococcal disease, certain populations such as those ≥ 65 years of age as well as 
younger individuals with specific chronic medical conditions continue to experience high 
pneumococcal-related mortality rates [8–10].
Many factors contribute to the increased susceptibility of older adults to pneumococcal 
disease. Age-related changes in immune function, including immunosenescence, impaired 
splenic function and changes in the respiratory tract appear to play a role [11,12]. Residence 
in a post-acute or long-term care facility increases risk as evidenced by several documented 
outbreaks or clusters of pneumococcal disease [13–17]. Medication use, including 
polypharmacy, is also common in the treatment of older adults. Prescribed medications may 
include immunosuppressive drugs and central nervous system (CNS) active agents that can 
increase risk of aspiration and/or respiratory depression and further increase the risk of 
pneumococcal infection. The increased susceptibility and mortality among specific 
populations as well the emergence of antibiotic resistant strains drove the consideration of 
methods for primary prevention, namely the development of pneumococcal vaccines [4,7].
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PNEUMOCOCCAL VACCINES AND ACIP RECOMMENDATIONS
Pneumococcal polysaccharide vaccine (PPSV) was first commercially developed and 
licensed for use in 1977 as a 14-valent vaccine (PPSV14). In 1983, a 23-valent vaccine 
(PPSV23) was licensed (Table 1), and in 1984 the ACIP recommended the PPSV23 for 
adults ≥ 65 and those with chronic illness at increased risk of pneumococcal disease [1]. 
This recommendation extends to nearly all adults residing in PA/LTC facilities. The vaccine 
reduced the incidence of invasive pneumococcal disease in immunocompetent adults. 
However, limited studies led to questions about the effectiveness of PPSV23 in high-risk 
adults [18]. Unfortunately this hampered uptake of the vaccine throughout the 1990’s and 
early 2000’s, and ultimately prompted a search for a more effective vaccine.
In 2000, a new 7-valent pneumococcal vaccine, the pneumococcal conjugate vaccine 
(PCV7), was licensed for use in the pediatric population (<18 years of age) [19]. PCV7 
reduced the rate of pneumococcal-related illness in children. Remarkably, administration of 
PCV7 to children also correlated with a marked reduction in the rate of hospitalizations due 
to pneumonia in older adults, even though this population did not receive the vaccine 
directly [20]. Of note, the effect decline in hospitalization rates for pneumonia was greatest 
among people ≥ 85 years [21]. Adoption of PCV7 has also been associated with a reduction 
in adult mortality from IPD [22]. In 2010, PCV7 was replaced with an expanded PCV13 
vaccine. Given the reports of improved effectiveness of the conjugate vaccines, the 
Community Acquired Pneumonia Immunization Trial in Adults (CAPITA) was launched in 
the Netherlands, a country in which PPSV23 had not been administered widely [23]. The 
CAPITA study randomized almost 85,000 adults ≥ 65 years of age (>26,000 were 75 years 
or older) to receive either PCV13 or placebo. PCV13 reduced vaccine-type invasive 
pneumococcal disease by 75% and vaccine-type community acquired pneumonia by 45%. 
Unfortunately, the study did not include a comparison to PPSV23, so could not answer the 
question of which vaccine is more effective at preventing pneumococcal-related illnesses.
Several studies of PCV13 and PPSV23 affirm that even very frail individuals benefit from 
pneumococcal vaccination. Immunogenicity studies comparing PCV13 and PPSV23 in frail 
elderly patients have been conducted in both nursing home and hospital settings. Subjects 
recruited in these studies included very frail elderly individuals with significant levels of 
dependency and cognitive impairment. Regardless of setting, subjects were able to mount a 
significant antibody response, including those with no detectable baseline levels of 
immunity [24,25]. A placebo controlled study of PPSV23 conducted in 1006 Japanese 
nursing home residents found a significant reduction in pneumococcal and all cause 
pneumonia rates. This study also reported a striking 35% absolute risk reduction in deaths 
from pneumococcal pneumonia [26]. While PCV13 may elicit a stronger immune response 
[27,28], the incidence of infections caused by the strains covered by the vaccine have 
declined [2]. In contrast, while PPSV23 may be less immunogenic, it offers protection 
against more strains [27,28].
In 2014, weighing the totality of evidence available to date, the ACIP recommended the use 
of both vaccines in adults 65 years or older in addition to those with chronic health 
conditions [2]. The ACIP determined that use of both vaccines provided benefit surpassing 
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that of either one alone. The 2014 ACIP recommendations included complex 
recommendations for intervals between vaccine administration. In 2015, the ACIP simplified 
the vaccine interval recommendations [29] with the intent to improve vaccine uptake as well 
as bring current recommendations into congruence with CMS coverage policies [30]. Table 
2 lists current ACIP recommendations and Figure 1 shows the recommended dosing 
intervals for PCV13 and PPSV23 administration [29]. Figure 2 provides an algorithm to help 
guide determination of vaccine administration in vaccine-naïve adults based on age, high- 
and low-risk conditions [31]. Depending on their indications, adults may receive up to 3 
doses of PPSV23 during their lifetime (2 doses at age <65 years; 1 dose at age ≥65 years), 
all of which should be given 5 years apart.
REGULATORY ATTEMPTS TO IMPROVE PNEUMOCOCCAL VACCINATION 
RATES IN PA/LTC FACILITIES
Several regulatory initiatives have been undertaken to improve pneumococcal vaccination 
rates in PA/LTC populations. In 2002, the United States Department of Health and Human 
Services (DHHS) issued orders allowing the use of standing order programs in nursing 
homes for influenza and pneumococcal vaccination [32]. Research had shown standing order 
programs to be effective in improving immunization rates and in 2000, the ACIP had 
recommended their use in a variety of clinical settings [33,34]. Despite their explicit 
allowance, standing order programs were not widely adopted, and influenza and 
pneumococcal vaccination rates remained well below targets. This led the Centers for 
Medicare & Medicaid Services (CMS) to issue a new immunization standard (F334) in 2005 
as part of the nursing facility conditions of participation [35]. This regulation requires 
PA/LTC facilities to assess the influenza and pneumococcal vaccination status of each 
resident, provide education about the vaccines and offer the vaccines to all eligible residents 
[36]. Additional 2009 updates to the PA/LTC facility infection control guidance (F441) 
emphasized the importance of vaccination by directing surveyors to investigate whether 
facilities have systems in place to ensure immunization of residents when assessing a 
facility’s overall infection control practices [36]. In July 2012, CMS began public reporting 
of a set of new quality measures. Included in these measures were two pertaining to 
pneumococcal vaccination: the percentage of short and long stay residents who have been 
assessed and appropriately given the pneumococcal vaccine [37].
By explicitly allowing and promoting standing order programs, promulgating immunization 
standards, tightening the survey investigative protocol for pneumococcal vaccination, and 
initiating public reporting of pneumococcal vaccination rates, CMS has made it clear that 
pneumococcal vaccination is a high priority. CMS expects facilities to have effective and 
current pneumococcal vaccination programs in place as part of their infection control 
activities.
BARRIERS TO PNEUMOCOCCAL IMMUNIZATION IN NURSING HOMES
The United States DHHS Healthy People 2020 Program has established a 90% 
pneumococcal vaccination rate goal for all adults (≥18 years) who reside in PA/LTC 
facilities. While pneumococcal vaccination rates among nursing home residents have 
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improved from 67% in 2006, they have since stagnated around 80%. Moreover, concerns 
have been raised about the accuracy of this data, and it is possible that vaccination rates may 
be lower than those reported [38,39]. There are many potential barriers to vaccination in 
general including poor access to vaccines, lack of education, healthcare worker behaviors 
and attitudes, cultural factors and cost [40,41]. A full discussion of such barriers is beyond 
the scope of this paper. However there are several key points relevant to pneumococcal 
vaccination of PA/LTC residents that deserve comment.
First, PA/LTC practitioners have voiced skepticism regarding the benefits of pneumococcal 
vaccinations. PA/LTC practitioners appropriately recognize frailty as a characteristic of 
PA/LTC residents and a potential attenuator of vaccine response [24,31,42]. Pneumococcal 
disease poses a serious health threat to residents and one in which prevention, by necessity, 
must play a prominent role. The data presented above provides evidence supporting the use 
of pneumococcal vaccine even in frail populations. While not as effective compared to use in 
younger and/or healthier populations, pneumococcal vaccination still provides a significant 
benefit to frail recipients. The Society has established a clear policy statement on 
pneumococcal vaccination in the PA/LTC setting, detailed in the following section.
Second, obtaining an accurate vaccine history is a challenge. Despite the prevalence of 
electronic health records, transfer of important vaccination information remains suboptimal 
and poses challenges as recently highlighted in the National Quality Forum’s 2015 report, 
Priority Setting for Healthcare Performance Measurement: Addressing Performance 
Measure Gaps for Adult Immunizations [43]. Facilities should seek ways to improve 
communication about a resident’s vaccination status at admission and discharge. Third, there 
have been questions regarding reimbursement from Medicare for pneumococcal vaccines. 
As PCV13 and PPSV23 are ACIP recommended vaccines, CMS has issued statements of 
coverage for both vaccines as a Part B benefit [23]. Fourth, and the most challenging barrier, 
is the complexity of vaccine recommendations. Given the complexities of current ACIP 
pneumococcal vaccination recommendations and the unique features of PA/LTC settings, it 
is understandable that pneumococcal vaccinations pose a challenge to many PA/LTC 
providers. As noted, ACIP recommendations have been simplified and algorithms such as 
the ones in Figures 1 and 2 exist to guide practitioners in selecting the right vaccine for each 
resident. Still, facilities will need to be familiar with specific indications for the vaccine and 
perform a thoughtful assessment of each resident.
POLICY STATEMENT, RECOMMENDATIONS AND TOOLS FROM THE 
SOCIETY’S INFECTION ADVISORY COMMITTEE (IAC)
AMDA – The Society for Post-Acute and Long-Term Care Medicine (The Society) strongly 
supports pneumococcal vaccination of PA/LTC residents and the need for continued efforts 
to improve pneumococcal vaccination rates. Box 1 details The Society’s policy statement 
regarding pneumococcal vaccination developed by the Infection Advisory Committee (IAC) 
and adopted by The Society.
The Society has created a series of educational and implementation tools to assist PA/LTC 
providers when assessing residents for pneumococcal vaccination needs. Available at the 
Nace et al. Page 6













Society’s website and found in Appendices 1–3, these tools were developed by the IAC and 
approved by The Society’s Board. They are introduced here with the aim of supporting 
provider efforts to improve pneumococcal vaccination rates among the PA/LTC population.
The tools include:
• A Pneumococcal Vaccination Guidance document formatted using a frequently 
asked question approach. The Guidance addresses common pneumococcal 
vaccination questions, and presents a series of common clinical vignettes 
designed to help providers select appropriate vaccination strategies. (see 
Appendix 1)
• A Pneumococcal Vaccination Coverage document that also uses a frequently 
asked question approach to answer questions about CMS coverage of 
pneumococcal vaccinations. (see Appendix 2)
• A Resident Pneumococcal Vaccination Assessment Note which helps nursing 
home staff complete the required resident pneumococcal vaccination assessment 
through use of a template note. (see Appendix 3)
The tools are available free of charge to assist PA/LTC providers and facilities. They can be 
found in the online appendix, as well as through The Society website [Pneumococcal 
Vaccination Guidance for PA / LTC Facilities]. The Society plans to update these materials 
as ACIP recommendations change. Finally, The Society welcomes feedback on this material 
in an effort to make improvements and to continue to support PA/LTC practitioners and 
facilities in their efforts to vaccinate their residents as an effective means to reduce the risk 
of infection with S. pneumoniae and improve clinical care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
REFERENCES
1. Centers for Disease Control (CDC). Update: pneumococcal polysaccharide vaccine usage--United 
States. MMWR Morb. Mortal. Wkly. Rep. 1984; 33:273–276. 281. [PubMed: 6425629] 
2. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 
23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of 
the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 
2014; 63:822–825. [PubMed: 25233284] 
3. Meisel ZF, Metlay JP, Sinnenberg L, et al. A randomized trial testing the effect of narrative vignettes 
versus guideline summaries on provider response to a professional oganization clinical policy for 
safe opioid prescribing. Ann. Emerg. Med. 2016 [Accessed 2 July 2016] 0. Available at: http://
www.annemergmed.com/article/S0196064416002055/abstract. 
4. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: 
implications for therapy of community-acquired bacterial pneumonia. Int. J. Antimicrob. Agents. 
2010; 36:197–204. [PubMed: 20558045] 
5. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate 
vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising 
conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR Morb. Mortal. Wkly. Rep. 2012; 61:816–819. [PubMed: 23051612] 
Nace et al. Page 7













6. Tilghman R, Finland M. Clinical significance of bacteremia in pneumococcic pneumonia. Arch. 
Intern. Med. 1937; 59:602–619.
7. Rocha P, Baleeiro C, Tunkel A. Impact of Antimicrobial Resistance on the Treatment of Invasive 
Pneumococcal Infections. Curr. Infect. Dis Rep. 2000; 2:399–408. [PubMed: 11095884] 
8. Navarro-Torné A, Dias JG, Hruba F, et al. Risk factors for death from invasive pneumococcal 
disease, Europe, 2010. Emerg. Infect. Dis. 2015; 21:417–425. [PubMed: 25693604] 
9. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal 
disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on 
community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015; 70:984–989. 
[PubMed: 26219979] 
10. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the 
era of antibiotic resistance, 1995–1997. Am. J. Public Health. 2000; 90:223–229. [PubMed: 
10667183] 
11. Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. Effects of ageing and gender on 
naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated 
proteins. Clin. Vaccine Immunol. 2008; 15:1391–1397. [PubMed: 18596205] 
12. Krone CL, van de Groep K, Trzciński K, Sanders EAM, Bogaert D. Immunosenescence and 
pneumococcal disease: an imbalance in host–pathogen interactions. Lancet Respir. Med. 2:141–
153.
13. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal 
pneumonia and bacteremia among unvaccinated nursing home residents. N. Engl. J. Med. 1998; 
338:1861–1868. [PubMed: 9637804] 
14. Thomas HL, Gajraj R, Slack MPE, et al. An explosive outbreak of Streptococcus pneumoniae 
serotype-8 infection in a highly vaccinated residential care home, England, summer 2012. 
Epidemiol. Infect. 2015; 143:1957–1963. [PubMed: 25298247] 
15. Tan CG, Ostrawski S, Bresnitz EA. A preventable outbreak of pneumococcal pneumonia among 
unvaccinated nursing home residents in New Jersey during 2001. Infect. Control Hosp. Epidemiol. 
2003; 24:848–852. [PubMed: 14649774] 
16. Olver WJ, Cavanagh J, Quinn M, Diggle M, Edwards GFS. Investigation and control of a cluster of 
penicillin non-susceptible Streptococcus pneumoniae infections in a care home. J. Hosp. Infect. 
2008; 70:80–83. [PubMed: 18621445] 
17. Kuroki T, Ishida M, Suzuki M, et al. Outbreak of Streptococcus pneumoniae serotype 3 pneumonia 
in extremely elderly people in a nursing home unit in Kanagawa, Japan, 2013. J. Am. Geriatr. Soc. 
2014; 62:1197–1198. [PubMed: 24925560] 
18. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: A meta-
analysis of randomized controlled trials. Arch. Intern. Med. 1994; 154:2666–2677. [PubMed: 
7993150] 
19. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants 
and young children. Recommendations of the Advisory Committee on Immunization Practices 
(ACIP). MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep. Cent. Dis. Control. 
2000; 49:1–35.
20. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in 
the era of conjugate vaccine. J. Infect. Dis. 2010; 201:32–41. [PubMed: 19947881] 
21. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia 
after a decade of pneumococcal vaccination. N. Engl. J. Med. 2013; 369:155–163. [PubMed: 
23841730] 
22. Grau I, Ardanuy C, Cubero M, Benitez MA, Liñares J, Pallares R. Declining mortality from adult 
pneumococcal infections linked to children’s vaccination. J. Infect. 2016; 72:439–449. [PubMed: 
26868606] 
23. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against 
pneumococcal pneumonia in adults. N. Engl. J. Med. 2015; 372:1114–1125. [PubMed: 25785969] 
24. MacIntyre CR, Ridda I, Gao Z, et al. A randomized clinical trial of the immunogenicity of 7-valent 
pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, 
hospitalized elderly. PLOS ONE. 2014; 9:e94578. [PubMed: 24760002] 
Nace et al. Page 8













25. Namkoong H, Funatsu Y, Oishi K, et al. Comparison of the immunogenicity and safety of 
polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or 
older in Japan: an open-labeled randomized study. Vaccine. 2015; 33:327–332. [PubMed: 
25448102] 
26. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in 
preventing pneumonia and improving survival in nursing home residents: double blind, 
randomised and placebo controlled trial. BMJ. 2010; 340:c1004. [PubMed: 20211953] 
27. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent 
pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine 
in pneumococcal vaccine-naive adults. Vaccine. 2013; 31:3577–3584. [PubMed: 23688526] 
28. Paradiso PR. Pneumococcal Conjugate Vaccine for Adults: A New Paradigm. Clin. Infect. Dis. 
2012; 55:259–264. [PubMed: 22495545] 
29. Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. 
Mortal. Wkly. Rep. 2015; 64:944–947. [PubMed: 26334788] 
30. Centers for Medicare. [Accessed 2 July 2016] Modifications to Medicare part B coverage of 
pneumococcal vaccinations. 2015. Available at: https://www.cms.gov/Medicare/Prevention/
PrevntionGenInfo/Health-Observance-Mesages-New-Items/2015-01-29-Pneumococcal.html
31. Perez F, Jump RLP. New developments in adult vaccination: Challenges and opportunities to 
protect vulnerable veterans From pneumococcal disease. Fed. Pract. 2015; 32:12–18. [PubMed: 
26924922] 
32. [Accessed 31 August 2016] Federal Register | Medicare and Medicaid Programs; Conditions of 
Participation: Immunization Standards for Hospitals, Long-Term Care Facilities, and Home Health 
Agencies. Available at: https://www.federalregister.gov/articles/2002/10/02/02-25096/medicare-
and-medicaid-programs-conditions-of-participation-immunization standards-for-hospitals
33. Bardenheier BH, Shefer A, McKibben L, Roberts H, Rhew D, Bratzler D. Factors predictive of 
increased influenza and pneumococcal vaccination coverage in long-term care facilities: The 
CMS-CDC standing orders program project. J. Am. Med. Dir. Assoc. 2005; 6:291–299. [PubMed: 
16165069] 
34. Postema AS, Breiman RF. National Vaccine Advisory Committee. Adult immunization programs 
in nontraditional settings: quality standards and guidance for program evaluation. MMWR 
Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep. Cent. Dis. Control. 2000; 49:1–13.
35. [Accessed 31 August 2016] Federal Register | Medicare and Medicaid Programs; Condition of 
Participation: Immunization Standard for Long Term Care Facilities. Available at: https://
www.federalregister.gov/articles/2005/10/07/05-19987/medicare-and-medicaid programs-
condition-of-participation-immunization-standard-for-long-term-care
36. [Accessed 31 August 2016] Medicare State Operations Manual, Appendix PP: Interpretive 
Guidelines for Long-Term Care Facilities. Available at: https://www.cms.gov/Regulations-and-
Guidance/Guidance/Manuals/Internet-Only-Manuals-IOMs-Items/CMS1201984.html
37. Smith, Laura, Zheng, Nan, Tracy, Kissam, Stephanie, et al. [Accessed 31 August 2016] Nursing 
Home MDS 3.0 Quality Measures: Final Analytic Report. Available at: https://www.cms.gov/
Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/
NHQIQualityMeasures.html
38. Pu Y, Dolar V, Gucwa AL. A comparative analysis of vaccine administration in urban and non-
urban skilled nursing facilities. BMC Geriatr. 2016; 16:148. [PubMed: 27473125] 
39. Data Chart | Healthy People 2020. [Accessed 1 September 2016] Available at: https://
www.healthypeople.gov/2020/data/Chart/4672?category=1&by=Total&fips=-1
40. Nace DA. Improving immunization rates in long-term care: Where the forest stops and the trees 
begin. J. Am. Med. Dir. Assoc. 2008; 9:617–621. [PubMed: 18992692] 
41. Jessop AB, Hausman AJ. Pneumococcal vaccination in pennsylvania nursing homes: factors 
associated with vaccination level. J. Am. Med. Dir. Assoc. 2002; 3:347–351. [PubMed: 12807601] 
42. Hamza SA, Mousa SM, Taha SE, Adel LA, Samaha HE, Hussein DA. Immune response of 23-
valent pneumococcal polysaccharide vaccinated elderly and its relation to frailty indices, 
Nace et al. Page 9













nutritional status, and serum zinc levels. Geriatr. Gerontol. Int. 2012; 12:223–229. [PubMed: 
21951819] 
43. NQF. Priority Setting for Healthcare Performance Measurement: Addressing Performance Measure 




Nace et al. Page 10














AMDA - THE SOCIETY FOR POST-ACUTE AND LONG-TERM CARE 
MEDICINE POLICY STATEMENT ON PNEUMOCOCCAL VACCINATION
• The Society strongly advocates that Post-Acute and Long-Term Care (PA/
LTC) facilities and providers establish and maintain a pneumococcal 
vaccination program that provides residents with access to current Advisory 
Committee on Immunization Practices (ACIP) and Centers for Disease 
Control and Prevention (CDC) recommended pneumococcal vaccinations.
• Such a program would include a requirement to assess PA/LTC residents for 
their pneumococcal vaccination status and to administer and document 
appropriate pneumococcal vaccinations in accordance with current ACIP and 
CDC guidance, unless the PA/LTC resident declines or has a medical 
contraindication or allergy,
• In addition, The Society recommends PA/LTC facilities and providers 
demonstrate an ongoing commitment to Quality Assessment and Performance 
Improvement by evaluating and addressing their pneumococcal vaccination 
programs if vaccine acceptance rates fall below U.S. Department of Health 
and Human Services goals.
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Advisory Committee on Immunization Practices (ACIP) recommended intervals for 
sequential use of PCV13 and PPSV23 for immunocompetent adults aged ≥65 years. **For 
adults aged ≥65 years with immunocompromising conditions, functional or anatomic 
asplenia, cerebrospinal fluid leaks, or cochlear implants, the recommended interval between 
PCV13 followed by PPSV23 is ≥8 weeks. For those for who previously received PPSV23 
when aged <65 years and for whom an additional dose of PPSV23 is indicated when aged 
≥65 years, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years 
after the most recent dose of PPSV23. Depending on their indications, adults may receive up 
to 3 doses of PPSV23 during their lifetime (2 doses at age <65 years; 1 dose at age ≥65 
years), all of which should be given 5 years apart. These materials were adapted from [29].
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Algorithm for Pneumococcal Immunization for Adults. These recommendations, based on 
[2,5], are for adults who have not previously received a pneumococcal vaccine. Figure 
adapted with permission from [31].
Nace et al. Page 13

























Nace et al. Page 14
TABLE 1
Pneumococcal Vaccines Available in the United States























PCV 7 Pneumococcal conjugate –
contains cell capsule






Licensed for children only. Not
used in older adults.
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TABLE 2
Summary of the Advisory Committee on Immunization Practices recommended intervals, by risk and age 
groups, for adults with indications to receive to PCV13 and PPSV23.

















No underlying chronic conditions NAc ≥1 year NAc ≥1 year
Immunocompetent persons











weeks ≥1 year ≥1 yearCerebrospinal fluid leak
Cochlear implant




weeks ≥1 year ≥1 yearSickle cell disease/other hemaglobinopathy





≥1 year ≥1 year
Congenital or acquired immunodeficiency













PCV13, polysaccharide-protein conjugate vaccine against 13 pneumococcal serotypes; PPSV23, polysaccharide vaccine against 23 pneumococcal 
serotypes.
c
NA, not applicable. Sequential use of PCV13 and PPSV23 is not recommended for these age and risk groups.
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